- Lobbying
- Lobbying by Pharmaceutical Research and Manufacturers of America
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeff MacKinnon | LD & LA Rep. Joe Barton (RTexas) LD & LA Rep. Joe Barton (RTexas) |
Jeffery Mortier | Prof Staff on E&C Cmte LA Rep Whitfield and Intern Devin Nunes Prof Staff on E&C Cmte LA Rep Whitfield and Intern Devin Nunes |
Sarah Walter | Former Legislative Director/Chief Counsel, Sen. John Breaux Former Legislative Director/Chief Counsel, Sen. John Breaux |
Edward Whitfield | U.S. Representative (21 yrs.) |
Dylan Moore | Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8) Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) |
Kristen Bautz | Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz |
Jody Gale | n/a |
William Krieger | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: General representation. Regulations and legislation relating to PBMs and drug pricing..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate